The first multicentric approach to childhood acute lymphoblastic leukemia (ALL) treatment in Italy started in the early 1970s when the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) was founded. Since then the AIEOP has conducted nationwide chemotherapy protocols. Results obtained in three different periods (1982-1986, 1987-1990, 1991-1995) are reported here. Treatment schedules have been characterized by a progressive intensification of systemic therapy and by a progressive substitution of protracted intrathecal therapy for cranial irradiation as central nervous system (CNS) preventive therapy. In the third period cranial radiotherapy (CRT) has been administered only to patients at high risk of relapse or with CNS involvement at diagnosis (about 15% of the overall population). A progressive improvement of therapeutic results, with a steady reduction of isolated CNS relapse rates have been obtained in the three periods considered here. The AIEOP experience shows that CRT can be safely omitted in non-high risk patients, unless they are T-ALL patients with WBC count at the diagnosis у100 000/mm 3 , and that intensification of treatment allows the improvement of overall results with a reduction of the impact of NCI prognostic criteria. Over the years, AIEOP has also continued to foster active cooperation at an international level. In the ongoing AIEOP ALL 2000 study, conducted in cooperation with the BFM group, patients are stratified according to the presence of translocations t(9;22) and t(4;11) and to treatment response (either initial steroid therapy or induction) or minimal residual disease). This cooperation will allow an adequate recruitment of patients to answer relevant randomized questions in the context of a study in which patients are stratified according to minimal residual disease findings. Leukemia (2000) 14, 2196-2204.
Introduction
Since the early 1970s, the Italian Association of Pediatric Hematology and Oncology (AIEOP) has adopted multicenter nationwide chemotherapy protocols for treatment of childhood acute lymphoblastic leukemia (ALL). Chemotherapy schedules and the possibility of running clinical trials have progressively improved during these years, following the development of AIEOP, which comprises at present 37 pediatric centers. [1] [2] [3] [4] [5] [6] The aim of this paper is to summarize the therapeutic strategy and the long-term results of the ALL studies conducted during the 1980s and the 1990s by AIEOP.
Patients and methods
From 1982 to 1995, a total of 3124 consecutive patients younger than 15 years of age with newly diagnosed ALL were enrolled into four studies. The diagnosis was based on morphologic evaluation of bone marrow aspirates and negative staining for myeloperoxidase or Sudan Black. Complete immuno-phenotyping has been routinely evaluated since 1987. 7 
Treatment
Details of chemotherapy regimens have been provided elsewhere [1] [2] [3] [4] [5] [6] and are summarized in Figure 1 . In brief, studies 82 and 87 were characterized by risk-adapted combination chemotherapy, associated with CNS-directed therapy with 1800 cGy of cranial radiotherapy (CRT) to intermediate-risk (IR) or high-risk (HR) patients, and intrathecal (IT) chemotherapy. Study 88 introduced intensive, BFM-type chemotherapy, largely derived from the BFM-ALL86 study, 8 with the major modification that CRT was replaced by extended IT chemotherapy in IR patients. 5 In study 91, stratification criteria were modified with the use of the 'in vivo' response to steroid prephase to identify 'prednisone poor responders' (PPR: у1000/mm 3 blasts in the peripheral blood after 7 days of steroids and one injection of intrathecal methotrexate, IT-MTX). 9 CRT was restricted to HR patients (approximately 15%), for whom treatment intensification with block therapy was introduced. 6 Main features of these four studies are summarized below.
Study 82
From August 1982 to February 1987, all patients with newly diagnosed non-B ALL, who were aged 1 to less than 15 years, were eligible for this study. Standard risk (SR) criteria were: white blood cell (WBC) count less than 10 000/mm 3 , age 3 to Ͻ6 years, non-T immunophenotype, no mediastinal mass, FAB morphology L1 (or Ͻ10% L2). IR criteria: non-T immunophenotype, no mediastinal mass and WBC count Ͻ10 000/mm 3 with age Ͻ3 or у6 years, or FAB morphology L2; or WBC count у10 000/mm 3 and Ͻ50 000/mm 3 with FAB morphology L1 or L2. HR criteria: all the remaining patients. As previously reported, 3 SR and IR patients had a three-drug induction therapy; IR patients had CRT with 1800 cGy and reinduction therapy with vincristine and prednisone. HR patients were treated until 1985 with a six-drug induction, followed by high-dose (HD) cytarabine, and a four-drug reinduction; CRT was not used. Because poor results were noted at interim analysis, this HR protocol (8303) was closed in February 1985 and replaced by protocol 8503, which consisted of the IR group therapy intensified by the introduction of daunomycin in induction phase, and by 20 weekly high doses of Lasparaginase (L-ASP) given during reinduction and continuation therapy. No IT therapy was administered during CRT.
Figure 1
Treatment schedule in four-study protocols performed by AIEOP in the period 1982-1995, according to stratification into standard (SR), intermediate (IR) and high (HR) risk groups (percentages represent patients' distribution in risk groups). A, Adriamicin; Ara-C, cytosine arabinoside; BCNU, carmustine; CPM, cyclophosphamide; D, daunomicyn; DXM, dexamethasone; Gy, Grays; HD-ARA-C, high-dose Ara-C (3 g/m 2 , four doses); HD-L-ASP, high-dose L-ASP (20 doses); HD-MTX, high-dose MTX (four courses); HU, hydroxyurea; ID-MTX, intermediatedose MTX (three courses); L-ASP, L-asparaginase; 6-MP, 6-mercaptopurine; MTX, methotrexate; P, prednisone; 6-TG, thioguanine; V, vincristine; ⇓, MTX intrathecal; R, randomization; ٌ, intrathecal Ara-C;̄, triple intrathecal (MTX, Ara-C, methylprednisolone); Ia, BFM's protocol Ia (V, P, D, L-ASP); Ib, BFM's protocol Ib (CPM, ARA-C, 6-MP); II, BFM's protocol II (V, DXM, A, L-ASP, CPM, 6-TG, Ara-C); II*, BFM's protocol II modified (V, DXM, A (two doses), L-ASP, CPM, 6-TG, Ara-C); III, BFM's protocol III (V, A, DXM, L-ASP, 6-TG, Ara-C). Treatment duration was 2 years for all schedules except that for HR-83 of protocol 82 (15 months). Note: spaces given for each phase in the schedule are not proportional to actual phase duration.
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Continuation therapy was based on oral 6-mercaptopurine (6-MP) and weekly i.m. methotrexate (MTX). Total duration of therapy was 24 months for all patients.
Study 87
The study was open to enrolment of non-B ALL patients aged 1 to less than 15 years from March 1987 to April 1991. SR criteria were: WBC count less than 10 000/mm 3 , age comprised between 3 and less than 7 years, non-T immunophenotype, no 'leukemia-lymphoma syndrome' (LLS, defined as the presence of massive splenomegaly, or massive adenopathy, or mediastinal mass + one or more laboratory findings including: T-immunophenotype, Hb Ͼ10 g/dl, WBC у50 000/mm 3 ), FAB morphology L1; IR criteria: non-T immunophenotype, no LLS, FAB morphology L1 or L2 with WBC count Ͻ10 000/mm 3 and age Ͻ3 or у7 years, or WBC count у10 000/mm 3 and Ͻ50 000/mm 3 ; HR criteria: all the remaining patients. Treatment schedule, as reported elsewhere, 4 was largely based on the previous study 82, with the following treatment modifications: (1) daunomycin was added in the induction therapy for SR and IR patients; (2) a three-drug reinduction was also given to non-HR patients; (3) IT-MTX (three doses) was also administered during CRT in the HR group. Intermediate-dose MTX was given to HR patients.
Study 88
From February 1988 to March 1992, AIEOP conducted another ALL study, largely similar to the 87 study, based on the BFM-ALL 86 study. 8 All children aged Ͻ15 years were eligible for the study. SR included patients with low tumor burden defined as BFM risk factor (calculated as: RF = 0.2 × log 10 (blast cell count +1) + 0.06 × cm of palpable liver + 0.04 × cm of palpable spleen) 9 Ͻ0.8; IR included children with RF у0.8 but Ͻ1.2; the HR group included children with RF у1.2, or t(9;22) clonal translocation or mediastinal mass or extramedullary leukemia, or CNS leukemia, and the patients who failed to achieve complete remission (CR) at the end of protocol Ia. The participation in this study was restricted to 10 experienced centers. The aims of this study were: (1) to assess the feasibility and the therapeutic impact of intensive chemotherapy for ALL in our multicenter setting; (2) in order to reduce the long-term toxicity, extended IT-MTX was substituted for CRT in IR patients. 5 
Study 91
From March 1991 to April 1995, the AIEOP-ALL 91 study was conducted in 37 AIEOP institutions and recruited children Ͻ15 years. SR group included patients aged у1 year, non-T ALL, with low tumor burden defined as BFM RF less than 0.8, who also were prednisone good responders (PGR); IR group included children with PGR, RF у0.8 but Ͻ1.7, or with RF Ͻ0.8 and either age Ͻ1 year or T immunophenotype. HR group included children with RF у1.7, or with t(9;22) or t(4;11) clonal translocations, or PPR, or who failed to achieve CR at the end of protocol Ia. The aim of the study was to assess: (1) the effect of the addition of protracted HD-L-ASP to a BFM backbone, in non-HR patients evaluated in a prospective, randomized study; (2) the effect of extended triple IT (TIT) chemotherapy substitution for CRT in all non-HR patients (ie Ͼ80% of the overall patients population); (3) the clinical impact of a reduction of the treatment intensity in the SR group and of an intensification in the HR group by adopting a novel therapeutic approach (based on the experience of the BFM studies for ALL relapses) mainly consisting of intensive polychemotherapy blocks. 10 
Statistical analysis
Event-free survival (EFS) and survival time are defined from the date of diagnosis until the date of failure. In EFS, failure is defined as one of the following events: no CR (considered as a failure at time zero), death in induction, relapse, death in CR, or development of a second malignancy. In survival, the failure is death from any cause. For subjects with no failure, EFS and survival times are censored at the last follow-up date. On average, those lost to follow-up are approximately 3% of the enrolled population. EFS and survival distributions are estimated according to Kaplan-Meier with standard errors (s.e.) according to Greenwood, and the log-rank test is used for their comparison. Cumulative incidence functions of isolated CNS relapse and of CNS relapse in conjunction with another type of relapse are estimated accounting for all other failures in term of competing events.
11 Follow-up was updated as of August 1999.
Results

Protocol-specific treatment outcome Study 82:
Out of 997 children enrolled in participating institutions, 46 patients were not eligible and 49 patients were not evaluable. Of the 902 eligible and evaluable patients, 855 (94.8%) attained CR; induction death rate was 2.2%. Death in CR occurred in 2.7% of the patients. The overall EFS (SE) at 5 and 10 years was 56.4% (1.7) and 52.7% (1.7), respectively; the overall survival at 10 years was 63.7% (1.6) . The cumulative risk of isolated CNS relapse at 10 years was 10.1% (1.0) and that of CNS relapse was 13.9% (1.2) (Figure 2 ). About 50% of patients could be cured with this risk-based therapy; about 75% of the patients were not exposed to alkylating agents or epipodophyllotoxins, and received a very low cumulative dosage of anthracyclines. Although the relapse rate was relatively high, in non-HR patients a 10-year survival rate of 72.4% (1.7) was obtained; EFS in SR and IR patients was 56.4% (4.7) and 61.2% (2.0), respectively. Second malignant neoplasms (SMN) occurred in five patients: two astrocytomas, one Hodgkin disease, one thyroid carcinoma and one unknown at 8, 9, 4, 8 and 15 years from the diagnosis of ALL, respectively.
Study 87:
Out of 694 children enrolled in participating institutions, 14 patients were not eligible and 48 patients were not evaluable. Of the 632 eligible and evaluable patients, 619 (97.9%) attained CR; induction death rate was 0.7%. Death in CR occurred in 1.1% of the patients. The overall EFS (SE) at 5 and 10 years was 67.0% (1.9) and 62.8% (2.0), respectively. The overall survival at 10 years was 74.7% (1.8) . The cumulative risk of isolated CNS relapse at 10 years was 8.2% (1.1) and that of CNS relapse was 10.9% (1.2) (Figure 3) . A significant improvement of the results (both CR and long-term survival rates) in respect of the previous study 82 was associated with treatment intensification, achieved by using an anthracycline-containing induction and reinduction therapy for all patients. No SMN were reported in this study.
Study 88:
Out of 438 children enrolled in participating institutions, 14 patients were not eligible and 28 patients were not evaluable. Of the 396 eligible and evaluable patients, 375 (94.7%) attained a CR; induction death rate was 1.3%. Death in CR occurred in 1.3% of the patients. The overall EFS (s.e.) at 5 and 10 years was 67.8% (2.4) and 65.1% (2.4), respectively. The overall survival at 10 years was 75.5% (2.2) . The cumulative risk of isolated CNS relapse at 10 years was 5.1% (1.1) and that of CNS relapse was 8.9% (1.4) (Figure 4 ). Substitution of extended IT-MTX for CRT in the IR group treated with intensive, BFM-type chemotherapy, allowed a 10-year isolated CNS cumulative risk of 0.9% (0.9) to be obtained. On the other hand, SR patients treated with less intensive reinduction therapy (protocol III instead of protocol II), HD-MTX (5 g/m 2 ), but not receiving extended IT-MTX during maintenance chemotherapy, had a 6.5% (2.8) cumulative risk of isolated CNS relapse. No SMN were reported in this study.
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Study 91:
Out of 1267 children enrolled in participating institutions, 25 patients were not eligible and 48 patients were not evaluable. Of the 1194 eligible and evaluable patients, 1152 (96.5%) attained CR; induction death rate was 1.4%. Death in CR occurred in 1.8% of the patients. The overall EFS (SE) at 5 and 8 years was 70.8% (1.3) and 68.5% (1.5), respectively. The overall survival at 8 years was 77.4% (1.4). The cumulative risk of isolated CNS relapse at 8 years was 1.5% (0.4) and that of CNS relapse was 2.6% (0.5) ( Figure 5 ). Subanalyses confirmed that in IR patients with lower tumor burden (i.e. RF between 0.8 and 1.2) CRT may be safely replaced by extended TIT 5 and suggested that IR patients with T-ALL and WBC count over 100 000/mm 3 (accounting for about 1% of the total population) may require CRT to achieve optimal results. 12 Intensive block therapy did not improve results in HR patients, who had a 5-year EFS of 39.7% (3.5) . As for the randomised study on the introduction of HD-L-ASP, in the SR group, the analysis is planned for the near future, whereas in the IR group no significant difference was observed between the disease-free survival in the two treatment arms (P value = 0.64), with estimated values at 7 years from randomization of 72.4% (3.1) and 75.7% (2.6) in the no-HD-L-ASP and HD-L-ASP arms (Erwinia product), respectively
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Figure 4
AIEOP non-B-ALL '88. Survival, event-free survival and incidence of CNS relapse (396 patients).
Figure 5
AIEOP non-B-ALL '91. Survival, event-free survival and incidence of CNS relapse (1194 patients).
(unpublished observations). Two SMN (one Rhabdomyosarcoma and one non-Hodgkin lymphoma) have been observed in this study, both at 4 years from the diagnosis.
Treatment results according to presenting features in each period (Tables 1-4)
Results reported here belong to three subsequent periods. The first period included study 82 (Table 1) , the second the two almost simultaneous studies 87 (Table 2 ) and 88 (Table 3) , and the third study 91 (Table 4) . Female patients showed a steady improvement in treatment results over the years, likely associated with treatment intensification. Improvement was less marked for males. Infants (less than 1 year of age) have been included in the second and third period studies and only about 30% of them were cured regardless of the period. Prognosis for patients with WBC counts exceeding 100 000/mm 
Discussion
Results obtained over the years in childhood ALL AIEOP studies confirm that treatment intensification and improved supportive care produced a progressively higher cure rate, with about 70% patients surviving event-free at 8 years in the period 1991-1995. Optimal CNS-directed treatment in childhood ALL remains questionable. Although the primary aim of this treatment is to reduce the incidence of leukemia relapse in the CNS, the treatment design must consider that the use of CRT is associated with undesired severe late effects. 13, 14 For this reason AIEOP has steadily decreased over the last 20 years the proportion of patients undergoing CRT while increasing intensity of both systemic and CNS-directed chemotherapy. IT-therapy consisted of IT-MTX or TIT. Results obtained for IR patients not irradiated who were treated with TIT in study 91 were identical to those obtained with IT-MTX only in study 88. 6 The frequency of irradiated patients decreased from 88% in the first period (study 82), to 88% and 49%, respectively, in studies 87 and 88, in the second period, and to 17% in the more recent period (study 91). This therapeutic strategy was associated with a marked decrease of the long-term probability of developing isolated CNS relapse, from 10% in the first period (Figure 2) to 7% in the second period (on the basis of cumulative results of studies 87 and 88, Figures 3 and 4) , to 1.5% in the last period ( Figure 4 ). Nevertheless the progressive decrease in the CNS relapse rate did not translate in an equivalent improvement in the EFS rate. This could be partly explained by excess of marrow relapses due to suboptimal treatment results in the HR group in the last period. Overall results obtained in the three periods show that in the first period, in which limited treatment intensity had been applied, very poor results were obtained in patients classified as HR by NCI criteria, in infants, in T-ALL and in males. In the second period treatment intensification allowed a clear improvement in the prognosis of these subgroups. Results of the third period suggest that block therapy may be inferior to a traditional BFM treatment for patients classified at HR by NCI criteria or with WBC count Ͼ100 000/mm 3 or T-ALL or PPR. This suggestion was confirmed by comparative evaluation of HR patients (defined as PPR, or failure to achieve CR at the end of induction therapy (protocol Ia), or presence of t(4;11) or t(9;22) clonal translocations treated in the third period (study 91) and in the subsequent period, study 95 (not shown here) in which better results were obtained by using a novel intensive chemotherapy schedule, which also includes a double delayed intensification with a repeated protocol II.
15,16
Future plans
On the basis of the information obtained from the I-BFM-SG study on the use of PCR for detection of minimal residual disease (MRD) in the early 1990s, 17 and on the more recent experience in treatment of HR patients with study 95, 16 the AIEOP group in cooperation with the German-Austrian-Swiss BFM group, has opened the current AIEOP-BFM-ALL 2000 study. In this study, SR patients are selected only according to treatment response, either PGR or MRD. For these patients limited treatment reduction is applied. Conversely, HR patients are defined by poor response to treatment (either PPR or no CR after 5 weeks of treatment with protocol Ia or persistently high levels of MRD after 11 weeks of therapy), or by the presence of t(4;11) or t(9;22) clonal translocations. For these patients an intensive chemotherapy schedule which also includes a double delayed intensification with a repeated protocol II 15, 16 is used. All the remaining patients are classified as IR and treated with a traditional BFM chemotherapy schedule. 
